Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Atlas, CMEA Test New Biotech Model

This article was originally published in Start Up

Executive Summary

Two high-profile VCs, CMEA Capital and Atlas Venture, are trying their hands at asset financing, an investment strategy that prioritizes single drug programs over companies and is becoming, at least theoretically, possible to do in a more systematic way. That's because big drug companies have cut internal R&D staff, often in drastic measure, and they want someone to share the development risk of drugs now sitting idle on their shelves.

You may also be interested in...



Anticoagulant Maker XO1 Takes $11M In Index Ventures’ Largest Series A

A chance discovery at a U.K. hospital led to the synthesis of an antibody that could prevent blood clots without causing excessive bleeding. Index Ventures created and funded single-asset company XO1 to conduct first-in-man tests on the compound by 2015.

CMEA 8 Is Kaput, But A Would-Be Partner Moves On With Wellspring

Just this past January, CMEA was touting its upcoming eighth fund and two new partners with a string of early-stage biotech successes on their resumes. The fund is now dissolved, but one would-be CMEA 8 partner has moved on with a new asset-centric incubator.

CMEA 8 Is Kaput, But A Would-Be Partner Moves On With Wellspring

Two months ago, CMEA was touting its upcoming eighth fund and two new partners with a string of early-stage biotech successes on their resumes. The fund is now dissolved, but one would-be CMEA 8 partner has moved on with a new asset-centric incubator.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

SC092099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel